CoChat

Amylin as a Future Obesity Treatment

Open access
Dehestani, Babak, Stratford, Nicholas RS, Roux, Carel W le · 2021 · Journal of Obesity & Metabolic Syndrome

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Obesity is defined as abnormal or excessive fat accumulation that contributes to detrimental health impacts. One-third of the population suffers from obesity, and it is important to consider obesity as a chronic disease requiring chronic treatment. Amylin is co-secreted with insulin from β pancreatic cells upon nutrient delivery to the small intestine as a satiety signal, acts upon sub-cortical homeostatic and hedonic brain regions, slows gastric emptying, and suppresses post-prandial glucagon responses to meals. Therefore, new pharmacological amylin analogues can be used as potential anti-obesity medications in individuals who are overweight or obese. In this narrative review, we analyse the efficacy, potency, and safety of amylin analogues. The synthetic amylin analogue pramlintide is an approved treatment for diabetes mellitus which promotes better glycaemic control and small but significant weight loss. AM833 (cagrilintide), an investigational novel long-acting acylated amylin analogue, acts as a non-selective amylin receptor. This calcitonin G protein-coupled receptor agonist can serve as an attractive novel treatment for obesity, resulting in reduction of food intake and significant weight loss in a dose-dependent manner.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7570/jomes21071

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Amylin functions as a satiety hormone. Released into the bloodstream by β pancreatic cells, amylin activates various homeostatic and reward centres in the brain to suppress appetite and reduce food intake. In addition, amylin acts as an inhibitory signal to delay gastric emptying and suppress the release of glucagon from α pancreatic cells. POMC, proopiomelanocortin; ARC, arcuate nucleus; BNST, bed nucleus of the stria terminalis; NTS, nucleus tractus solitarius; LPBN, lateral parabrachial nucleus; AP, area postrema.
Figure 1 Amylin functions as a satiety hormone. Released into the bloodstream by β pancreatic cells, amylin activates various homeostatic and reward centres in the brain to suppress appetite and reduce food intake. In addition, amylin acts as an inhibitory signal to delay gastric emptying and suppress the release of glucagon from α pancreatic cells. POMC, proopiomelanocortin; ARC, arcuate nucleus; BNST, bed nucleus of the stria terminalis; NTS, nucleus tractus solitarius; LPBN, lateral parabrachial nucleus; AP, area postrema.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 72

Metadata

Authors
Dehestani, B., Stratford, N. R., & Roux, C. W. L.
Affiliations
University College Dublin (IE)
Corresponding author
Dehestani, Babak
Venue
Journal of Obesity & Metabolic Syndrome
Published
2021-12-30
Volume
30
Issue
4
Pages
320-325
ISSN
  • 2508-6235 (ISSN-L)
  • 2508-7576
OpenAlex
W4200574551
Cited by
72
References
38
Citations by year
2026: 17 · 2025: 22 · 2024: 16 · 2023: 12 · 2022: 5
FWCI
1.04
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • creativecommons.org/licenses/by-nc/4.0/ (tdm)
Locations
  • Journal of Obesity & Metabolic Syndrome (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
amylin, amylin analogues, obesity treatment, pramlintide, cagrilintide, amylin receptor, satiety, gastric emptying, weight loss, dietary intake, anti-obesity drugs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amylin as a Future Obesity Treatment. https://app.cochat.ai/papers/10.7570/jomes21071
The paper
Dehestani, B., Stratford, N. R., & Roux, C. W. L. (2021). Amylin as a Future Obesity Treatment. Journal of Obesity & Metabolic Syndrome. https://doi.org/10.7570/jomes21071

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.